Antiseptic efficacy of a low-dosed topical triclosan/chlorhexidine combination therapy in atopic dermatitis

Skin Pharmacology and Physiology

Volumn 20, Issue 2, 2007, Pages 71-76

  Wohlrab, J ^a,d   Jost, G ^c   Abeck, D ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Skin Center Harlaching   (Germany)

^c Spirig Pharma Ltd   (Switzerland)

^d MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Atopic dermatitis; Chlorhexidin; Staphylococcus aureus; Triclosan

Indexed keywords

CHLORHEXIDINE; LIPODERM; TRICLOSAN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; BACTERIOLOGICAL TECHNIQUES; CHLORHEXIDINE; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EMULSIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; TRICLOSAN;

EID: 33847782775     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097653     Document Type: Article

References (25)

1. Kim HJ, Honig PJ: Atopic dermatitis. Curr Opin Pediatr 1998;10:387-392.
2. Bartzokas CA, Corkill JE, Makin T, Pinder DC: Assessment of the remanent antibacterial effect of a 2% triclosan-detergent preparation on the skin. J Hyg (Lond) 1983;91:521-528.
3. Aliaga A, Castells A, Kriznik D, Lalosevic J, Marron J, Moragas J, Ocana J, Schindlery C: An overview of two comparative multicentre trials with halometasone/triclosan cream in acute superficial bacterial skin infections. J Int Med Res 1983;11:53-57.
4. Vischer WA, Regos J: Antimicrobial spectrum of Triclosan, a broad-spectrum antimicrobial agent for topical application. Zentralbl Bakteriol [Orig A] 1974;226:376-389.
5. Perrenoud D, Bircher A, Hunziker T, Suter H, Bruckner-Tuderman L, Stäger J, Thürlimann W, Schmid P, Suard A, Hunziker N: Frequency of sensitization to 13 common preservatives in Switzerland. Swiss Contact Dermatitis Research Group. Contact Dermatitis 1994;30:276-279.
6. Barkvoll P, Rolla G: Triclosan reduces the clinical symptoms of the allergic patch test reaction (APR) elicited with 1% nickel sulphate in sensitised patients. J Clin Periodontol 1995;22:485-487.
7. Kjaerheim V, Barkvoll P, Waaler SM, Rolla G: Triclosan inhibits histamine-induced inflammation in human skin. J Clin Periodontol 1995;22:423-426.
8. Barkvoll P, Rolla G: Triclosan protects the skin against dermatitis caused by sodium lauryl sulphate exposure. J Clin Periodontol 1994;21:717-719.
9. Bhargava HN, Leonard PA: Triclosan: applications and safety. Am J Infect Control 1996;24:209-218.
10. Moss T, Howes D, Williams FM: Percutaneous penetration and dermal metabolism of triclosan (2,4,4′-trichloro-2′-hydroxydiphenyl ether). Food Chem Toxicol 2000;38:361-370.
11. Guillen J, Bernabeu A, Shapiro S, Villalain J: Location and orientation of Triclosan in phospholipid model membranes. Eur Biophys J 2004;33:448-453.
12. Sivaraman S, Sullivan TJ, Johnson F, Novichenok P, Cui G, Simmerling C, Tonge PJ: Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. J Med Chem 2004;47:509-518.
13. Regos J, Zak O, Solf R, Vischer WA, Weirich EG: Antimicrobial spectrum of triclosan, a broad-spectrum antimicrobial agent for topical application. 2. Comparison with some other antimicrobial agents. Dermatologica 1979;158:72-79.
14. Moss T, Howes D, Williams FM: Percutaneous penetration and dermal metabolism of triclosan (2,4,4′-trichloro-2′-hydroxydiphenyl ether). Food Chem Toxicol 2000;38:361-370.
15. Bamber AI, Neal TJ: An assessment of triclosan susceptibility in methicillin-resistant and methicillin-sensitive Staphylococcus aureus. J Hosp Infect 1999;41:107-109.
16. Gehring W, Forssmann T, Jost G, Gloor M: Die keimreduzierende Wirkung von Erythromycin und Triclosan bei der atopischen Dermatitis. Akt Dermatol 1996;22:28-31.
17. Wilcox MH, Hall J, Gill AB, Fawley WN, Parnell P, Verity P: Effectiveness of topical chlorhexidine powder as an alternative to hexachlorophane for the control of Staphylococcus aureus in neonates. J Hosp Infect 2004;56:156-159.
18. Brockow K, Grabenhorst P, Abeck D, Traupe B, Ring J, Hoppe U, Wolf F: Effect of gentian violet, corticosteroid and tar preparations in Staphylococcus aureus-colonized atopic eczema. Dermatology 1999;199:231-236.
19. Oranje AP, Stalder JF, Taieb A, Tasset C, de Longueville M: Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. ETAC Study Group. Early Treatment of the Atopic Child. Pediatr Allergy Immunol 1997;8:28-34.
20. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A: Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10-19.
21. European Task Force on Atopic Dermatitis: Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23-31.
22. Williamson P, Kligman AM: A new method for the quantitative investigation of cutaneous bacteria. J Invest Dermatol 1965;45:498-503.
23. Rajka G, Langeland T: Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989;144:13-14.
24. Roll A, Cozzio A, Fischer B, Schmid-Grendelmeier P: Microbial colonization and atopic dermatitis. Curr Opin Allergy Clin Immunol 2004;4:373-378.
25. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-1160.